Katy Talento questioned why Medicare relies on pharmacy benefit managers instead of negotiating directly with pharmaceutical companies. Read More »
Sally Pipes of Pacific Research Institute said new federal proposals could bring needed transparency and accountability to the expanding 340B Drug Pricing Program. Read More »
Jackson Hammond of Paragon Health Institute called for reforms to end spread-based profit mechanisms in the federal 340B drug discount program. Read More »
Steve Forbes criticized the current state of the 340B drug discount program in a recent statement. Read More »
Kevin Roche said that hospitals have turned the federal 340B drug pricing program into a profit source rather than using it solely for poor patients as intended. Read More »
Former Governor Bobby Jindal said recent pharmacy benefit manager (PBM) reforms are an important first step toward greater transparency in drug pricing. Read More »
The American Legislative Exchange Council said on March 9 that the federal 340B Drug Pricing Program increases costs for taxpayers and patients while failing many underserved communities. Read More »
PhRMA released an analysis showing 340B hospitals buy drugs at discounts but apply high markups when billing insurers and patients. Read More »
Peter Mihalick of the American Medical Informatics Association said that the federal 340B Drug Pricing Program incentivizes nonprofit hospitals to prioritize profits over patient savings. Read More »
U.S. Representative Gabe Evans said pharmacy benefit managers have contributed to rising prescription drug costs and highlighted recent congressional action aimed at reforming their practices. Read More »
Dae Y. Lee called attention to a proposed Department of Labor rule that would require pharmacy benefit managers to reveal details about their revenue practices. He encouraged stakeholders to submit public comments before the March 31 deadline. State audits and legal actions have highlighted ongoing concerns over spread pricing and retroactive fees. Read More »
Anthony DiGiorgio from UCSF highlights concerns regarding the financial impact of the 340B drug discount program on taxpayers and employer plans. Read More »
The rapid expansion of the 340B Drug Pricing Program has sparked concerns over its effectiveness in improving access or reducing costs. Read More »
The article discusses concerns raised about pharmacy benefit managers' (PBMs) impact on drug costs due to opaque pricing strategies. Read More »
The article discusses Anthony DiGiorgio's insights on how the federal 340B Drug Pricing Program incentivizes hospital consolidation by favoring high-priced drugs over independent oncologists. Read More »
Mark Cuban emphasizes breaking up vertically integrated insurers for true healthcare price relief. Read More »
The federal 340B program is projected to grow significantly next year due to increased participation rather than rising drug prices. Read More »
Pharmacy benefit managers face scrutiny as calls grow for increased oversight due to widespread U.S. pharmacy closures affecting millions living in "pharmacy deserts." Read More »
The Senate HELP Committee recently held a hearing to address concerns over the growth of the U.S.'s largest drug-purchasing channel under the 340B program. Read More »
Anthony M. DiGiorgio, DO, MHA, an assistant professor of neurosurgery at the University of California, San Francisco (UCSF), expressed concerns about the 340B program during an appearance on the Healthcare Unfiltered podcast. Read More »
Alerts Sign-up
